{
  "slug": "ema-european-medicines-agency",
  "name": "European Medicines Agency (EMA)",
  "description": "The European Medicines Agency (EMA) facilitates the development and access to medicines for countries within the European Union (EU). It evaluates applications for marketing authorisation submitted via the centralised procedure, monitors the safety of medicines across their lifecycle, and provides information to healthcare professionals and patients for human, veterinary, and herbal medicines.",
  "url": "https://optimly.ai/brand/ema-european-medicines-agency",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/ema.europa.eu",
  "baiScore": 33,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Regulatory Agency",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-09T00:03:19.886Z",
  "verifiedVitals": {
    "website": "https://ema.europa.eu",
    "pricing_model": "Not applicable as a public regulatory body (funded by the EU and fees, though not specified in text).",
    "core_products": "Evaluation, authorisation, and post-authorisation safety monitoring of human, veterinary, and herbal medicines for the EU/EEA; provision of public information and data on these medicines; crisis preparedness and management.",
    "key_differentiator": "Serves as the central scientific body responsible for assessing medicines for use across the entire EU/EEA, providing a unified regulatory standard and single market authorisation pathway for many medicines, distinct from fragmented national approval processes.",
    "target_markets": "European Union (EU) and European Economic Area (EEA) Member States, national regulatory authorities, pharmaceutical industry, healthcare professionals, and patients.",
    "subcategory": "Pharmaceutical Regulation"
  },
  "intentTags": {
    "problemIntents": [
      "Fragmented National Approvals: Each EU Member State would be solely responsible for evaluating and authorising medicines, leading to significantly increased costs, delays, and inconsistencies across t",
      "Unregulated Pharmaceutical Market: Without a central regulatory body, the EU pharmaceutical market would lack harmonised safety standards, leading to a higher incidence of unsafe or ineffective medici",
      "Private Regulatory Consulting: Pharmaceutical companies would heavily rely on private regulatory consulting firms to navigate a complex patchwork of national regulations, increasing development costs "
    ],
    "solutionIntents": [
      "medicine for human use",
      "search by active substance",
      "veterinary medicines information",
      "how to buy medicines online safely EU",
      "HIV and AIDS medicines latest updates"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1786402579493
}